

# Clinical, radiological and laboratory characteristics of pediatric patients with COVID-19: Living systematic review

*Características clínicas, radiológicas y de laboratorio en pacientes pediátricos con COVID-19. Revisión sistemática viva*

Santiago Vasco-Morales<sup>1,2</sup>  Cristhian Santiago Vasco-Toapanta<sup>3</sup>  Paola Cristina Toapanta-Pinta<sup>1,2</sup> 

<sup>1</sup> Universidad Central del Ecuador - Faculty of Medical Sciences - Obstetrics Program - Quito - Ecuador.

<sup>2</sup> Universidad de São Paulo - Faculty of Medicine of Ribeirão-Preto - São Paulo - Brazil.

<sup>3</sup> Universidad San Francisco de Quito - School of Health Sciences - Quito - Ecuador.

Corresponding author: Santiago Vasco-Morales. Programa de Obstetricia, Facultad de Ciencias Médicas, Universidad Central del Ecuador. Quito. Ecuador. Email: [snvasco@uce.edu.ec](mailto:snvasco@uce.edu.ec).

## Abstract

**Introduction:** Since the first COVID-19 cases were reported, the disease's clinical and epidemiological characteristics have continuously been studied, although they have not been yet defined.

**Objective:** To estimate the epidemiological profile of pediatric patients with COVID-19, as well as their clinical, laboratory and radiological characteristics.

**Materials and methods:** A living systemic review was conducted in the PubMed, Scopus and SciELO databases. Observational studies describing clinical, radiological, and laboratory characteristics of pediatric patients with COVID-19 and published between January 1, 2020, and July 20, 2020, were considered for the search; there were no language restrictions. Government, epidemiological, and pre-print papers were also considered. Meta-analyses of single proportion (frequentist approach) and two proportions (Bayesian method) were carried out. The study registration and protocol are available at <https://osf.io/y43wm> and <https://osf.io/r8ktv>, respectively.

**Results:** 13 studies, with a total of 9 152 patients, were retrieved. The Bayesian meta-analysis reported that males are more affected by the disease: OR 1.24 (HDI95%: 1.09-1.4). The proportion results calculated by means of the frequentist meta-analysis are: 52% cough (95%CI: 50-55), 0% death (95%CI: 0-0.1), 16% high aspartate transaminase levels (95%CI: 13-19), and 60% lung changes observed in chest X-ray (95%CI: 57-64).

**Conclusions:** Based on the current data, it is not possible to describe accurately the clinical and epidemiological characteristics of COVID-19 in the pediatric population. However, evidence suggests that males are more affected by the disease and that lung alterations in imaging studies are more frequent than clinical signs such as cough and fever. Laboratory test results are not conclusive and show that different organs and systems of the human body may be affected by SARS-CoV-2. The results reported here must be compared to prospective controlled studies conducted in larger samples and a more rigorous design.

**Keywords:** Children; COVID-19; Signs and symptoms; Laboratory; Radiology (MeSH).

Vasco-Morales S, Vasco-Toapanta CS, Toapanta-Pinta PC. Clinical, radiological and laboratory characteristics of pediatric patients with COVID-19: Living systematic review. Rev. Fac. Med. 2021;69(1):e90222. English. doi: <https://dx.doi.org/10.15446/revfacmed.v69n1.90222>.

## Resumen

**Introducción.** Desde que se reportaron los primeros casos de COVID-19, sus características clínicas y epidemiológicas han sido constantemente estudiadas, pero aún no han sido definidas.

**Objetivo.** Estimar el perfil epidemiológico, así como las características clínicas, radiológicas y de laboratorio en pacientes pediátricos con COVID-19.

**Materiales y métodos.** Se realizó una revisión sistemática viva en las bases de datos PubMed, Scopus y SciELO; para la búsqueda se consideraron estudios observacionales publicados entre enero 1 de 2020 y julio 20 de 2020, sin restricción de idioma, que describieran características clínicas, radiológicas y de laboratorio en población pediátrica con COVID-19; también se incluyeron reportes gubernamentales y epidemiológicos, y artículos publicados en formato pre-print. Se realizaron metaanálisis de proporción única (método frecuentista) y de dos proporciones (método bayesiano). El registro y el protocolo del estudio están disponibles en <https://osf.io/y43wm> y <https://osf.io/r8ktv>, respectivamente.

**Resultados.** Se encontraron 13 estudios, con un total de 9 152 pacientes. El metaanálisis bayesiano reportó una mayor afectación del sexo masculino: OR: 1.2 (HDI95%: 1.09-1.4). Los resultados de la proporción calculada por el metaanálisis frecuentista fueron: tos 52% (IC95%: 50-55), muerte 0% (IC95%: 0-0.1), niveles elevados de aspartato aminotransferasa 16% (IC95%: 13-19) y alteraciones pulmonares evidenciadas mediante estudios de imagen 60% (IC95%: 57-64).

**Conclusiones.** Con los datos actuales no es posible describir con exactitud las características clínicas y epidemiológicas de la COVID-19 en población pediátrica. Sin embargo, existen indicios de una mayor afectación al sexo masculino, y de que las anomalías pulmonares detectadas en radiografías y tomografías del tórax son más frecuentes que signos clínicos como la tos y la fiebre. Los resultados de laboratorio no son concluyentes y reflejan que diferentes órganos y sistemas son afectados por el SARS-CoV-2. Los hallazgos del presente estudio deben ser contrastados con estudios prospectivos controlados, con un mayor número de pacientes y un diseño más riguroso.

**Palabras clave:** Niños; COVID-19; Signos y síntomas; Laboratorio; Radiología (DeCS).

Vasco-Morales S, Vasco-Toapanta CS, Toapanta-Pinta PC. Características clínicas, radiológicas y de laboratorio en pacientes pediátricos con COVID-19. Revisión sistemática viva. Rev. Fac. Med. 2021;69(1):e90222. English. doi: <https://dx.doi.org/10.15446/revfacmed.v69n1.90222>.

## Introduction

COVID-19 is a disease caused by the SARS-CoV-2 coronavirus and the first cases were reported in Wuhan, China, in December 2019.<sup>1</sup> This disease has had serious consequences worldwide due to its rapid spread, so, since it was first identified, multiple investigations have been carried out to establish its clinical-epidemiological profile, which has not been clearly defined yet despite the significant advances in this regard.

In the pediatric population, COVID-19 was first described as a respiratory infection similar to seasonal influenza outbreaks, where most patients present with mild to moderate respiratory symptoms and occasional respiratory failure, and people with comorbidities are affected the most.<sup>2</sup>

Current data indicate that COVID-19 affects children and young people less frequently and less intensely, which could be explained by the reduced expression of the angiotensin-converting enzyme 2 (ACE2) receptor in this population, as it is used by SARS-CoV2 to enter the host cells from the nasal epithelium.<sup>3</sup>

In the lungs, SARS-CoV2 can cause alveolar damage by desquamation of pneumocytes, edema with mononuclear inflammatory cell infiltrate, and membrane deposit on the gas-exchange surface, resulting in ground-glass opacities patterns.<sup>4-6</sup>

Although respiratory conditions are most commonly observed, COVID-19 may also present with gastrointestinal symptoms such as abdominal pain, vomiting and diarrhea,<sup>7</sup> rash-like skin lesions, and even Kawasaki syndrome (a systemic vasculitis of unknown origin associated with bacterial or viral infections) as reported in the pediatric population.<sup>8</sup> Moreover, it has been reported that groups of children present with cardiac involvement, gastrointestinal symptoms, and significantly elevated markers of inflammation 2 to 4 weeks after developing SARS-CoV-2 infection. This form of presentation is known as multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19.<sup>9</sup>

Similarly, laboratory findings are variable and depend on the availability of tests in each hospital facility; for example, variations in blood count, blood chemistry, markers of inflammation and infection, among others, have also been reported.<sup>5,10</sup>

In this context, the objective of this review is to estimate the epidemiological profile of pediatric patients with COVID-19, as well as their clinical, laboratory and radiological characteristics.

## Materials and methods

A living systematic review was carried out after being granted technical approval by the Obstetrics Program Council of the Universidad Central del Ecuador. The study registration and protocol are available at <https://osf.io/y43wm> and <https://osf.io/r8ktv>, respectively.

### Search strategy

The acronym POT was considered for preparing this review as follows: P: patients under 19 years of age; O: outcome, which refers to the clinical, radiological, and laboratory characteristics of patients with a confirmed

diagnosis of COVID-19; and T: types of studies required, which for this review were cross-sectional and cohort studies, case series, and systematic reviews, all of them observational.

A living systematic search was carried out in the PubMed, Scopus and SciELO databases using the following search strategy: publication period: January 1, 2020 to July 20, 2020; types of study: government and epidemiological reports and pre-print articles describing clinical, radiological, and laboratory characteristics in the pediatric population with COVID-19; language: unrestricted; search terms: "2019-nCoV disease", "2019-nCoV infection", "SARS-CoV-2 infection", "coronavirus disease-19", "Child", "Children", "Pediatrics", "Infant", "Infants", "Adolescent" and "Preschool", which were combined with the operators "OR" and "AND" to establish the search equations.

### Inclusion criteria, quality of studies, risk of bias, and quality of evidence

According to the tools published by the Joanna Briggs Institute for critical appraisal of scientific literature,<sup>11,12</sup> studies that met the requirements to be classified as case series, cross-sectional studies, systematic reviews, and cohort studies were included.

By definition, observational studies provide low-quality evidence and, therefore, have a high risk of bias. To minimize this problem, the present study included only articles that scored  $\geq 70\%$  after the critical appraisal and were performed on at least 101 patients. The parameter to calculate the minimum sample size that the articles should have to be included in the present review was that fever and cough are found in approximately 50% of cases;<sup>13</sup> a precision of 10% with a 95% confidence was applied, thus resulting in a minimum number of 101 patients. The sample size was extrapolated for the rest of the studied variables.

To assess the quality of the evidence found, the GRADE handbook criteria were applied;<sup>14</sup> this system classifies the certainty of the evidence into very low, low, moderate, and high.

### Procedure for searching, extracting, and analyzing data

CV and SV conducted searches in the bibliographic databases, while SV and PT independently selected articles according to the title and reading of the abstract and applied inclusion criteria to select full-text articles; in case of disagreement, it was resolved by consensus by all authors. CV extracted the data and transferred them to the database format in a spreadsheet, and SV performed the frequentist and Bayesian statistical analyzes.

### Statistical analysis

To estimate the overall proportion of clinical, radiological and laboratory characteristics in patients, a meta-analysis of single proportion, i.e., single-arm meta-analysis, was performed using the frequentist method. In this way, data on variables of interest and sample size were extracted from the included studies, but interventions were not analyzed. For this meta-analysis, the statistical program R version 3.6.1,<sup>15,16</sup> which uses the inverse variance method and the generalized linear mixed model,

was utilized. The random effects model was also applied because it assumes that the included studies are a random sample of the universe of possibilities, making it more conservative.<sup>16</sup>

To identify and measure heterogeneity, the interpretation thresholds described in the Cochrane handbook were considered:<sup>17</sup> 0-40%: might not be important, 30-60%: may represent moderate heterogeneity, 50-90%: may represent substantial heterogeneity, and 75-100%: considerable heterogeneity. The results of the meta-analyses were not considered when heterogeneity in a data group was  $\geq 60\%$ .

Subgroup analyzes were also performed according to the origin of the patients. To calculate publication bias, the Egger’s linear regression test was applied. It was adjusted to be used with a minimum of 4 studies, establishing that  $p < 0.1$  suggested the presence of bias.

On the other hand, to estimate the Odds Ratio (OR), a meta-analysis of two proportions was performed using the Bayesian method. It has multiple advantages over the frequentist method; for example, the graphs accurately explain each parameter with the corresponding differences and the number of patients or sample size do not influence the results. It is also a model that is robust compared to atypical or heterogeneous values and determines that high heterogeneity leads to a greater variance of the subsequent estimate, which is easy to detect and therefore unlikely to lead to bias.<sup>18</sup>

The Bayesian model was applied using the Markov chain Monte Carlo (MCMC) method. To calculate these chains, the initial values of the variables under study were run 1 000 adaptation steps; then, in order for the chains to advance from their non-representative initial values to the area where the values of the later probability were found, another 1 000 steps were run —phase known as burn-in period—, and finally 30 000 steps were saved. The validity of the model was tested using the Heidelberger and Welch convergence diagnostic tests. For more information on the Bayesian model, see Achar *et al.*<sup>19</sup> and Kruschke.<sup>20</sup>

The programs used for data processing in this study are those employed by Kruschke & Liddell.<sup>18</sup> Data were analyzed using the R Project for Statistical Computing 3.6.1 program and rjags and coda packages.<sup>21,22</sup>

### Living systematic review


Due to its nature, the present living systematic review will be updated every six months according to the recommendations of Elliott *et al.*,<sup>23</sup> who indicate that when new studies or data are identified for inclusion, these data can be incorporated into the review as a brief communication or an editorial if the new information does not make negligible difference to summary estimates and has no effect on the findings of the review. In contrast, if new studies or data are identified that result in significant changes to summary estimates or the conclusions of the review, they should be submitted to a rapid editorial and peer review prior to publication.

### Results

The initial database search yielded 458 results, of which 131 were removed because they were duplicates, 231 were not related to the research subject, 75 did not meet the inclusion criteria, and 8 had poor quality or non-minimum sample compliance (101 patients). Finally, 13 studies were included for full analysis: 1 cross-sectional study, 1 cohort study, and 11 case series, which together described a total of 9 152 patients. Not all variables were made with the available data. The study selection flowchart is summarized in Figure 1.

Table 1 presents a summary of the demographic characteristics of each of the articles included. Sex was described in 9 019 patients and the total number of men affected was 4 867 (53.9%).

Table 2 presents in detail each of the clinical laboratory and radiological variables, with their partial and total values.



**Figure 1.** Flow chart for article selection. Source: Own elaboration.

**Table 1.** Distribution of patients according to sex and age groups in each study.

ID	Author	Average age *	Total patients	Male (%)	Country-region	Type of study	Features	Critical appraisal%
1	Lu <i>et al.</i> <sup>24</sup>	6 years	110	59 (53.63)	China	Case series	Single center	80
2	Xiong <i>et al.</i> <sup>25</sup>	3 years and 8 months	244	120 (62.17) †	China	Cross-sectional	Single center	75
3	Wu <i>et al.</i> <sup>26</sup>	84 months (IQR: 18-123 months)	148	60 (40.54)	China	Case series	Single center	70
4	Li <i>et al.</i> <sup>27</sup>	6 years (IQR: 1-9 years)	125	71 (56.8)	China	Case series	Single center	80
5	Dong <i>et al.</i> <sup>28</sup>	7 years (IQR: 2-13 years)	731	420 (57.45)	China	Case series	Multicenter	80
6	Lu <i>et al.</i> <sup>10</sup>	6.7 years (R: 1 day - 15 years)	171	104 (60.81)	China	Case series	Single center	80
7	DeBiasi <i>et al.</i> <sup>29</sup>	9.6 years	177	92 (51.97)	USA Washington, District of Columbia	Cohorts	Single center	75
8	CDC COVID-19 Response Team <sup>30</sup>	11 years (R: 0-17 years)	2 572	1 408(56.54) ‡	USA	Case series	Multicenter	70
9	Bellino <i>et al.</i> <sup>31</sup>	11 years (IQR: 5-15 years)	3 836	1 970 (51.35)	Italy	Case series	Multicenter	70
10	Garazzino <i>et al.</i> <sup>32</sup>	5 years (IQR: 0.3-9.6 years)	168	94 (55.95)	Italy	Case series	Multicenter	80
11	Armann <i>et al.</i> <sup>33</sup>	-	128	64 (50)	Germany	Case series	Multicenter	80
12	Gaborieau <i>et al.</i> <sup>34</sup>	1 year (R: 0.12-10 years)	157	94 (59.87)	France	Case series	Multicenter	80
13	Göttinger <i>et al.</i> <sup>35</sup>	5 years (IQR: 0.5-12 years)	585	311 (53.16)	Europe	Case series	Multicenter	80

ID=study identification number; R: range; IQR: interquartile range.

\* Maximum and minimum values are included in the studies. When the study reported the median age, the interquartile range was included. Some data were converted from months to years.

† This study describes sex in only 193 participants.

‡ This study describes sex in only 2 490 participants.

Source: Own elaboration.

**Table 2.** Distribution of participants according to clinical, laboratory and radiological characteristics.

Study		Lu <i>et al.</i> 24 n (%)	Xiong <i>et al.</i> 25 n (%)	Wu <i>et al.</i> 26 n (%)	Li <i>et al.</i> 27 n (%)	Dong <i>et al.</i> 28 n (%)	Lu <i>et al.</i> 10 n (%)	DeBiasi <i>et al.</i> 29 n (%)	CDC COVID-19 Response Team30 n (%)	Bellino <i>et al.</i> 31 n (%)	Garazzino <i>et al.</i> 32 n (%)	Armann <i>et al.</i> 33 n (%)	Gaborieau <i>et al.</i> 34 n (%)	Göttinger <i>et al.</i> 35 n (%)	Patients n (%)*	Total †	
Age group	Infant	-	77 (31.55)	-	49 (39.2)	86 (11.76)	31 (18.12)	43 (24.29)	398 (15.47)	-	66 (39.28)	47 (36.71)	90 (57.32)	230 (39.31)	1 117 (24.8)	4 504	
	Preschooler	-	24 (9.83)	-	22 (17.6)	137 (18.74)	40 (23.39)	26 (14.68)	291 (11.31)	-	38 (22.61)	37 (28.9)	15 (9.55)	62 (10.59)	692 (15.3)	4 504	
	Schooler	-	48 (19.67)	-	42 (33.6)	171 (23.39)	58 (33.91)	23 (12.99)	682 (26.51)	-	24 (14.28)	18 (14.06)	16 (10.19)	94 (16.06)	1 176 (26.1)	4 504	
	Adolescent	-	46 (18.85)	-	12 (9.6)	337 (46.1)	42 (24.56)	73 (41.24)	813 (31.6)	-	40 (23.8)	26 (20.31)	36 (22.92)	94 (16.06)	1 519 (33.7)	4 504	
Patient condition	Asymptomatic	29 (26.36)	51 (20.9)	45 (30.4)	21 (16.8)	94 (12.85)	-	-	-	785 (38.99) ‡	-	22 (17.18)	-	92 (15.72)	1 139 (19.28)	5 907	
	Mild respiratory infection	81 (73.63)	50 (20.49)	60 (40.54)	27 (21.6)	315 (43.09)	-	-	-	492 (24.38) ‡	-	52 (40.62)	-	313 (53.5)	1 390 (23.7)	5 856	
	Moderate infection	-	132 (54.09)	88 (59.45)	-	300 (41.03)	-	44 (24.85)	-	1242 (32.37)	-	20 (15.62)	-	143 (24.44)	1 969 (32)	6 145	
	Severe infection	-	7 (2.86)	6 (4.05)	77 (61.6)	-	-	35 (19.77)	147 (19.7) ‡	79 (3.87)	-	19 (14.84)	-	-	370 (6.9)	5 352	
	Serious-critical	-	4 (1.63)	3 (2.02)	-	3 (0.41)	-	9 (5.08)	15 (2) ‡	7 (0.28)	-	16 (12.5)	16 (10.19)	48 (8.2)	121 (1.7)	6 922	
	Death	-	1 (0.4)	2 (1.35)	-	1 (0.13)	1 (0.58)	0	3 (0.11)	4 (0.1)	-	1 (0.78)	3 (1.91)	4 (0.68)	19 (0.2)	8 401	
Place where the infection was acquired	Family group	-	159 (65.1)	-	-	-	154 (90.05)	-	168 (91) ‡	-	113 (67.26)	109 (85.15)	-	348 (59.48)	1 051 (27.5)	3 817	
	Other contacts	-	-	-	-	-	17 (9.94)	-	16 (9) ‡	-	-	-	-	234 (40)	267 (25.5)	1 047	
Signs and symptoms	Cough	57 (51.81)	120 (49.18)	-	-	-	83 (48.53)	99 (55.93)	157 (54) ‡	-	82 (48.8)	-	-	316 (54.01)	914 (53.9)	1 695	
	Fever	56 (50.9)	99 (40.57)	60 (40.54)	-	-	71 (41.52)	116 (65.53)	163 (56) ‡	-	138 (82.14)	86 (67.18)	116 (73.88)	327 (55.89)	1 232 (56.5)	2 179	
	Pharyngitis	-	10 (4.09)	-	-	-	79 (46.19)	77 (43.5)	71 (24.41) ‡	-	9 (5.35)	-	-	-	246 (23.4)	1 051	
	Headache	6 (5.45)	10 (4.09)	5 (3.37)	-	-	-	25 (14.12)	81 (27.83) ‡	-	-	-	-	70 (27.45) ‡	197 (16)	1 225	
	Rhinorrhea/ congestion	10 (9.09)	24 (9.83)	-	-	-	-	-	21 (7.21) ‡	-	45 (26.78)	-	57 (36.3)	-	157 (16.1)	970	
	Anosmia-ageusia	-	-	-	-	-	-	15 (8.47)	-	-	-	-	-	7 (4.45)	-	22 (6.5)	334
	Myalgia	3 (2.72)	9 (3.68)	-	-	-	-	25 (14.12)	-	-	-	-	-	-	37 (6.9)	531	
	Skin rash	-	-	-	-	-	-	1 (0.56)	-	-	-	-	-	14 (8.91)	-	15 (4.4)	334
	Dyspnea	-	11 (4.5)	-	-	-	49 (28.65)	27 (15.25)	38 (13) ‡	-	16 (9.52)	-	38 (24.2)	-	179 (14.8)	1 208	
	Vomiting/ diarrhea	26 (23.63)	34 (13.93)	32 (21.62)	-	-	-	27 (15.25)	37 (12.7) ‡	-	22 (13.09)	22 (17.18)	24 (15.28)	128 (21.88)	352 (17.5)	2 008	
Desaturation	-	9 (3.68)	-	-	-	4 (2.33)	-	-	-	-	-	-	-	74 (12.64)	87 (7.8)	1 110	
Total patients with comorbidities		-	-	-	13 (10.4)	-	-	69 (38.98)	80 (23) ‡	206 (5.37)	33 (19.64)	26 (20.31)	44 (28.02)	145 (24.78)	616 (8.8)	6 925	

**Table 2.** Distribution of participants according to clinical, laboratory and radiological characteristics. (Continued)

Study		Lu <i>et al.</i> 24 n (%)	Xiong <i>et al.</i> 25 n (%)	Wu <i>et al.</i> 26 n (%)	Li <i>et al.</i> 27 n (%)	Dong <i>et al.</i> 28 n (%)	Lu <i>et al.</i> 10 n (%)	DeBiasi <i>et al.</i> 29 n (%)	CDC COVID-19 Response Team30 n (%)	Bellino <i>et al.</i> 31 n (%)	Garazzino <i>et al.</i> 32 n (%)	Armann <i>et al.</i> 33 n (%)	Gaborieau <i>et al.</i> 34 n (%)	Göttinger <i>et al.</i> 35 n (%)	Patients n (%)*	Total †
Main comorbidities	Pulmonary	-	-	-	6 (4.8)	-	-	35 (19.77)	40 (11.49) ‡	23 (0.59)	7 (4.16)	15 (11.71)	7 (4.45)	29 (4.95)	162 (2.2)	7 280
	Cardiac	-	-	-	2 (1.6)	-	-	5 (2.82)	25 (7.18)	17 (0.44)	-	8 (6.25)	-	25 (4.27)	82 (1.1)	6983
	Hemato-oncological	-	-	1 (0.67)	1 (0.8)	-	-	8 (4.51)	-	11 (0.28)	4 (2.38)	4 (3.12)	-	27 (4.61)	56 (1.1)	4 727
	Neurological	-	-	-	1 (0.8)	-	-	11 (6.21)	-	6 (0.15)	5 (2.97)	5 (3.9)	-	26 (4.44)	54 (1.1)	4 579
Alterations in blood count	Leukocytosis	12 (10.9)	-	-	-	-	-	-	-	-	-	-	-	-	12 (10.9)	110
	Leukopenia	6 (5.45)	45 (18.44)	16 (10.81)	-	-	45 (26.31)	-	-	-	-	-	-	-	112 (7.3)	1 529
	Lymphopenia	-	-	7 (4.72)	1 (0.8)	-	5 (2.92)	-	-	-	-	-	-	-	13 (2.9)	444
Other lab tests	Elevated procalcitonin	52 (47.27)	-	70 (47.29)	61 (48.8)	-	105 (61.4)	-	-	-	-	-	-	-	288 (51.9)	554
	Elevated CRP	21 (19.09)	-	48 (32.43)	28 (22.4)	-	33 (19.29)	-	-	-	47 (38.37) ‡	-	-	-	177 (26.6)	675
	High AST	19 (17.27)	-	25 (16.89)	23 (18.4)	-	21 (12.28)	-	-	-	-	-	-	-	88 (15.8)	554
	High ALT	5 (4.54)	-	12 (8.1)	6 (4.8)	-	25 (14.61)	-	-	-	-	-	-	-	48 (8.6)	556
	Elevated D-dimer	11 (10)	-	-	-	-	21 (12.28)	-	-	-	-	-	-	-	32 (12.3)	260
Lung changes visible through chest x-ray and computed tomography scan		64 (62.1)	138 (56.55)	88 (59.45)	82 (65.8)	-	111 (64.91)	-	-	-	-	-	26 (72.22) ‡	93 (46.96)	602 (58.3)	1 032

CRP: C-reactive protein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactic dehydrogenase.

\* This column lists the number of patients who presented the event of interest.

† This column lists the total number of patients described in each variable.

‡ The n value and the percentage correspond to the number of patients who presented the event of interest in the corresponding variable.

Source: Own elaboration.

According to the age group, patients classified as schoolers and adolescents account for almost 60% of those affected. When analyzing the condition of the patients, it was found that the majority were asymptomatic or had mild respiratory infections, followed by moderate infections; conversely, patients with severe infections or a serious/critical condition represented low percentages (Table 2).

Regarding signs and symptoms, cough and fever were the most frequent and were found in more than half of the patients; other manifestations occurred in a smaller percentage (Table 2).

*Meta-analysis results, heterogeneity, and publication bias*

A meta-analysis of all clinical, laboratory and radiological variables was carried out. Table 3 reports the final results and shows the general proportion of the

variables that presented heterogeneity <60% and were described in at least 4 articles. The results of the Egger’s linear regression test did not show p-values <0.1, so there was no publication bias due to the effect of the small studies. Therefore, this criterion would only be valid for the variables cough, death and pulmonary alterations observed in imaging studies, which were the only ones found in 7 or more studies. In particular, the analysis of the variable death found significant heterogeneity (59%); however, most studies reported mortality <1%.

It should be noted that the level of heterogeneity found did not allow obtaining reliable results although the subgroups of the variable related to the place where the patient contracted the infection were analyzed. Nevertheless, the percentage of infected children within the family nucleus was higher in the Chinese population.


**Table 3.** Summary of the meta-analyses of single proportion.

Variables Ratio (95%CI)		Random effects model		Egger’s Regression (p-value)
		Heterogeneity I2 % (p-value)		
Clinical	Cough	52% (50-55)	0 (0.59)	0.58
	Death	0% (0-0.1)	59 (< 0.01)	
Lab test	High AST	16% (13-19)	0 (0.45)	0.18
Pulmonary alterations observed in imaging studies		60% (57-64)	28 (0.2)	0.1

Source: Own elaboration.

Figure 2 presents the tree diagram for the OR estimation. It plots the subsequent distribution of each parameter as a horizontal bar under the histogram; said bar represents the 95% (high probability density) HDI

(highest density interval), which is the Bayesian analogue of the 95%CI (confidence interval). HDI comprises the set of values containing the estimated OR for each data set. The gray triangle represents the sample size (n=).



**Figure 2.** Tree diagram for meta-analysis of two proportions according to sex.

Source: Own elaboration.

All studies reported the sex of the patients, which allowed to estimate the overall OR, showing that the 95%HDI does not include 1 (although it is very close). The OR logarithm, which represents the difference in the probability of disease among men/women, showed a modal distribution of 0.24 (95%HDI: 0.10-0.37); these values do not include 0 and, therefore, indicate that there is a greater involvement of the male sex.

**Quality of evidence**

Table 4 summarizes the quality of evidence found according to the GRADE criteria.<sup>14</sup>

When analyzing the variable death, a significant heterogeneity was found (59%), which was considered a serious inconsistency. However, evidence was eventu-

ally classified as high (Table 4) since all studies where this variable was described had a high quality and most reported mortality <1% (especially those that included a large number of patients).

**Discussion**

COVID-19 is a disease that has greatly impacted all the scenarios of human activity.<sup>36-38</sup> Like any infection caused by other coronaviruses such as SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus), SARS-CoV-2 affects the pediatric population in a smaller proportion.<sup>39,40</sup> However, it has similar clinical presentation and mortality rates than those reported for the first two viruses.

**Table 4.** Quality of evidence for articles found according to the GRADE criteria.

Result	No. of studies (No. of patients)	Study design	Factors that may reduce the certainty of the evidence					Certainty of evidence
			Risk of bias *	Indirect evidence †	Inconsistency ‡	Imprecision **	Other considerations	
Cough	7 (914)	Observational	Serious	Serious	Not serious	Not serious	Publication bias not detected.	Moderate
Death	10 (19)	Observational	Not serious	Not serious	Serious	Not serious	Publication bias not detected.	High
Elevated aspartate aminotransferase level	4 (88)	Observational	Very serious	Very serious	Very serious	Very serious	Publication bias not detected.	Very low
Pulmonary alteration observed in imaging studies	7 (602)	Observational	Serious	Serious	Not serious	Not serious	Publication bias not detected.	Moderate
Sex: more males affected	13 (4 867)	Observational	Serious	Serious	Not serious	Not serious	Publication bias not detected.	Moderate

\* This factor qualified the design or execution of the study.

† This factor evaluated whether the evidence found responded directly to the objective or research question.

‡ This factor evaluated whether the results were consistent between studies.

\*\* This factor evaluated whether the results were accurate enough.

Source: Elaboration based on Schünemann *et al.*<sup>14</sup>

When comparing COVID-19 with seasonal influenza, it is found that the clinical presentation of both diseases is variable and can range from asymptomatic cases, through mild cases, to serious infections. The population at highest risk of influenza virus infection are children, who are also the main transmitters, while, in the case of COVID-19, they seem to be the least affected.<sup>41</sup>

According to the results, COVID-19 occurs more frequently in males, which is consistent with the findings observed in adults, where the proportion of affected men is even higher. This increased susceptibility of the male sex may be due to multiple factors (biological and physiological) such as increased expression of the ACE2 receptor blockers or the presence of the double X chromosome to which a protective role is attributed.<sup>1</sup> In this context, it should be borne in mind that, in most regions, it is still men who work the most out of their homes, which increases the likelihood of infection; this

greater contact with people outside the home is also typical of schoolchildren and adolescents, which would explain why these age groups are more affected.<sup>4,42,43</sup>

Similarly, lockdowns have helped elucidate the source of the infection. In China, for example, the population was confined early, which is why it was established that most children were infected in their household, unlike populations where confinement started late and where most infections occurred is not clear.<sup>44</sup>

Underlying diseases condition susceptibility to infection by or worsening of COVID-19 symptoms. According to the studies analyzed, up to 50% of the severe or critical patients had comorbidities, mainly pulmonary, neurological, cardiovascular, or obesity, which is consistent with the reports in adults.<sup>10,45,46</sup>

COVID-19 may present with variable symptoms. In this regard, Wise<sup>47</sup> analyzed the data obtained from a symptom tracking application and reported that there



are six different “types” of COVID-19. Each type is characterized by a group of symptoms that are classified as follows: (i) “flu-like” without fever (headache, hyporexia, cough, odynophagia, myalgia, and chest pain); (ii) “flu-like” with fever (headache, hyporexia, anosmia, cough, dysphonia, odynophagia); (iii) gastrointestinal (headache, anosmia, hyporexia, diarrhea, odynophagia, and severe chest pain); (iv) severe level one: fatigue (headache, chest pain, anosmia, cough, fever, and dysphonia); (v) severe level two: confusion (headache, chest pain, myalgia, odynophagia, anosmia, hyperexia, cough, fever, and fatigue); and (vi) severe level three: abdominal and respiratory involvement (headache, odynophagia, chest pain, abdomen and muscles, anosmia, hyperexia, cough, fever, dysphonia, fatigue, confusion, respiratory distress, and diarrhea.) The same study reported that patients with clinical symptoms level 4 to 6 are more likely to be admitted to the hospital and need respiratory support,<sup>47</sup> which also coincides with the reports in the adult population.

In this regard, Xiong *et al.*<sup>25</sup> found that children with COVID-19 and gastrointestinal symptoms are prone to further deterioration of their clinical symptoms and alterations of lab test results. Moreover, several studies have reported the presence of SARS-CoV-2 in children’s feces even up to 30 days after infection,<sup>48</sup> although it is worth mentioning that the fecal-oral route has not yet been determined.<sup>49</sup>

It should be noted that cough and fever are the most common symptoms and that rates of up to 72.2% and 89.1%, respectively, have been reported in adults. In the pediatric population, the percentages are lower, which could be explained by the higher number of patients under 19 years of age who are asymptomatic or present with a mild infection.<sup>50</sup>

Laboratory test results are not conclusive since leukopenia is relatively frequent in viral processes in children;<sup>39</sup> however, only lymphopenia yielded results with a constant proportion, even though the number of studies found was not sufficient to estimate its overall proportion. It should be noted that lymphopenia occurs in greater proportion in adults and is considered a critical factor associated with the severity and mortality of the disease.<sup>5</sup> This may be related to both the characteristics of the immune system and the low percentage of severe/critical patients reported in the studies analyzed here.

With respect to inflammation and infection markers, the overall proportion of patients with elevated C-reactive protein and procalcitonin levels could not be established in this study. However, it should be noted that the results of both tests may be normal in patients with mild infections and that the elevation of these markers is associated with more severe clinical manifestations or bacterial coinfections.<sup>10,39,45</sup> The same occurs with the elevation of the D-dimer, which is usually accompanied by a systemic inflammatory response and coagulation activation in patients with severe symptoms.<sup>39,51</sup>

Lactate dehydrogenase and transaminases (aspartate aminotransferase and alanine aminotransferase) are elevated in infectious or inflammatory processes, and the latter increase even more when the liver is involved. Although the elevation of these enzymes is sometimes non-specific, measuring their increase can help assess systemic involvement when a patient is ill.<sup>39,45,52</sup>

Pulmonary ground-glass opacities were found in 60% of the patients analyzed in the studies included in the present review; however, this same pattern has been described in up to 96.6% of cases in adults.<sup>40,49,50</sup> In both groups, lung injury is most evident in computed tomography.<sup>5,53</sup>

The present work was prepared based on the best evidence available up to the date of the review, so it includes quality studies that are mostly multicenter. In addition, Bayesian methods were applied to calculate OR. Nevertheless, its limitations include that all data are reported in retrospective studies; the overall proportion in most variables presented high heterogeneity that may be associated with genetic, geographic or ethnic causes; there was a lack of stratification of the variables according to the different age groups since some symptoms can only be reported by patients older than five years, for example, headache or anosmia; and not all studies presented the variables analyzed and, therefore, the number of observations was not constant. Given these limitations, the results of this study should be contrasted with prospective randomized controlled studies with larger samples and a stricter design.

## Conclusions

Clinical and epidemiological characteristics of COVID-19 in pediatric patients cannot yet be accurately described based on the current data. However, the male sex seems to be more affected and lung alterations in imaging studies are more frequent than clinical signs such as cough and fever. Laboratory results are not conclusive and reflect that different organs and systems are affected by the virus.

This meta-analysis was prepared based on the best data available up to the date of the review and on a rigorous analysis, so the data are credible and will serve as the basis for future comparisons between regions or age groups.

## Conflicts of interest

None stated by the authors.

## Funding

None stated by the authors.

## Acknowledgments

None stated by the authors.

## References

1. Palacios-Cruz M, Santos E, Velázquez-Cervantes MA, León-Juárez M. COVID-19, una emergencia de salud pública mundial. *Rev Clínica Española*. 2020. <https://doi.org/ggqfmw>.
2. Ruiz-Matus C, Kuri-Morales P, Narro-Robles J. Comportamiento de las temporadas de influenza en México de 2010 a 2016, análisis y prospectiva. *Gac Med Mex*. 2017 [cited 2020 Dec 2];153:205-13. Available from: <https://bit.ly/3qlkyo0>.
3. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. *JAMA*. 2020;323(23):2427. <https://doi.org/fk55>.

4. Ng MY, Lee EY, Yang J, Yang F, Li X, Wang H, *et al.* Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review. *Radiol Cardiothorac Imaging*. 2020;2(1):e200034. <https://doi.org/ggrz6d>.
5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, *et al.* Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020;8(4):420-2. <https://doi.org/ggk6c5>.
6. Sun ML, Yang JM, Sun YP, Su GH. [Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020;43(0):E014. <https://doi.org/ggmwqjb>.
7. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, *et al.* Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement. *World J Pediatr*. 2020;16(3):223-31. <https://doi.org/ggq35v>.
8. Gianotti R, Recalcati S, Fantini F, Riva C, Milani M, Dainese E, *et al.* Histopathological Study of a Broad Spectrum of Skin Dermatoses in Patients Affected or Highly Suspected of Infection by COVID-19 in the Northern Part of Italy: Analysis of the Many Faces of the Viral-Induced Skin Diseases in Previous and New Reported Cases. *Am J Dermatopathol*. 2020;42(8):564-70. <https://doi.org/fk56>.
9. Buonsenso D, Di Sante G, Sali M, CURE COVID-19 Study Group. Cytokine Profile in an Adolescent With Pediatric Multisystem Inflammatory Syndrome Temporally Related to COVID-19. *Pediatr Infect Dis J*. 2020;39(8):e213-5. <https://doi.org/gg5kqs>.
10. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, *et al.* SARS-CoV-2 Infection in Children. *N Engl J Med*. 2020;382(17):1663-5. <https://doi.org/ggpt2q>.
11. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetc R, *et al.* Chapter 7: Systematic Reviews of Etiology and Risk. In: Aromataris E, Munn Z, editors. *JB I Manual for Evidence Synthesis*. JBI; 2020 [cited 2020 Aug 21]. <https://doi.org/fk57>.
12. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. *Int J Evid Based Healthc*. 2015;13(3):132-40. <https://doi.org/gfkpmq>.
13. Chang TH, Wu JL, Chang LY. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. *J Formos Med Assoc*. 2020;119(5):982-9. <https://doi.org/ggtxhh>.
14. Schünemann H, Brożek J, Guyatt G, Oxman A. Manual GRADE para calificar la calidad de la evidencia y la fuerza de la recomendación. P.A Orrego & M.X. Rojas (Trans) 2017 [cited 2020 Dec 2]. Available from: <https://bit.ly/33zUJGc>.
15. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019 [cited 2020 Dec 2]. Available from: <https://bit.ly/3mB0Cex>.
16. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Heal*. 2019;22(4):153-60. <https://doi.org/ggchpv>.
17. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, *et al.* *Cochrane Handbook for Systematic Reviews of Interventions*. Cochrane Training; 2019 [cited 2020 May 13]. Available from: <https://bit.ly/2JIZV4w>.
18. Kruschke JK, Liddell TM. The Bayesian New Statistics: Hypothesis testing, estimation, meta-analysis, and power analysis from a Bayesian perspective. *Psychon Bull Rev*. 2018;25(1):178-206. <https://doi.org/gc3gmn>.
19. Achar JA, Coelho-Barros EA, Molina-de Souza R, Martinez EZ. Uma introdução aos métodos bayesianos aplicados à análise de dados. Timburi/SP: Editora Cia do Ebook; 2019.
20. Kruschke JK. *Doing Bayesian Data Analysis: A Tutorial with R, JAGS, and Stan*. 2nd ed. Oxford: Elsevier Science; 2015.
21. Plummer M. Bayesian Graphical Models using MCMC [R package rjags versión 4-8].
22. Plummer M. Output Analysis and Diagnostics for MCMC [R package coda versión 0.19-3].
23. Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JPT, Mavergames C, *et al.* Living systematic reviews: an emerging opportunity to narrow the evidence-practice Gap. *PLoS Med* 11(2): e1001603. <https://doi.org/ggv7dp>.
24. Lu Y, Li Y, Deng W, Liu M, He Y, Huang L, *et al.* Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan. *Pediatr Infect Dis J*. 2020;39(7):e95-9. <https://doi.org/ggv2kp>.
25. Xiong X, Wong KKY, Chi S, Zhou A, Tang J, Zhou L-S, *et al.* Are COVID-19 infected children with gastrointestinal symptoms different from those without symptoms? A comparative study of the clinical characteristics and epidemiological trend of 244 pediatric cases from Wuhan. medRxiv; 2020. <https://doi.org/fk43>.
26. Wu H, Zhu H, Yuan C, Yao C, Luo W, Shen X, *et al.* Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China. *JAMA Netw Open*. 2020;3(6):e2010895. <https://doi.org/fm5n>.
27. Li Y, Deng W, Xiong H, Li H, Chen Z, Nie Y, *et al.* Immune-related factors associated with pneumonia in 127 children with coronavirus disease 2019 in Wuhan. *Pediatr Pulmonol*. 2020;55(9):2354-60. <https://doi.org/ghc6hf>.
28. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, *et al.* Epidemiology of COVID-19 Among Children in China. *Pediatrics*. 2020 [cited 2020 Aug 24] <https://doi.org/dqff>.
29. DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, *et al.* Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. *J Pediatr*. 2020;223:199-203.e1. <https://doi.org/ggx265>.
30. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(14):422-6. doi: <https://doi.org/ggrchw>.
31. Bellino S, Punzo O, Rota MC, Del Manso M, Urdiales AM, Andrianou X, *et al.* COVID-19 Disease Severity Risk Factors for Pediatric Patients in Italy. *Pediatrics*. 2020;146(4):e2020009399. <https://doi.org/gg69b3>.
32. Garazzino S, Montagnani C, Donà D, Meini A, Felici E, Vergine G, *et al.* Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. *Euro Surveill*. 2020;25(18):pii2000600. <https://doi.org/dvk8>.
33. Armann JP, Diffloth N, Simon A, Doenhardt M, Hufnagel M, Trotter A, *et al.* Hospital Admission in Children and Adolescents With COVID-19. *Dtsch Arztebl Int*. 2020;117(21):373-4. <https://doi.org/fk49>.
34. Gaborieau L, Delestrain C, Bensaid P, Vizeneuve A, Blanc P, Garraffo A, *et al.* Epidemiology and Clinical Presentation of Children Hospitalized with SARS-CoV-2 Infection in Suburbs of Paris. *J Clin Med*. 2020;9(7):2227. <https://doi.org/fk5d>.
35. Götzinger F, Santiago-García B, Noguera-Julían A, Lanaspá M, Lancellata L, Calò-Carducci FI, *et al.* COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health*. 2020;4(9):653-61. <https://doi.org/gg4bqz>.
36. Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, *et al.* Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. *Philos Trans R Soc London Ser B Biol Sci*. 2004;359(1447):1091-105. <https://doi.org/c2n646>.

37. Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, *et al.* Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur Rev Med Pharmacol Sci.* 2020;24(4): 2012-9. <https://doi.org/ggpxt5>.
38. Thabet F, Chehab M, Bafaqih H, AlMohaimed S. Middle East respiratory syndrome coronavirus in children. *Saudi Med J.* 2015;36(4):484. <https://doi.org/f68893>.
39. Calvo C, García López-Hortelano M, de Carlos-Vicente JC, Vázquez-Martínez JL. Recomendaciones sobre el manejo clínico de la infección por el «nuevo coronavirus» SARS-CoV2. Grupo de trabajo de la Asociación Española de Pediatría (AEP). *An Pediatría (Barc).* 2020;92(4):241.e1-11. <https://doi.org/ggpqxkq>.
40. Deng SQ, Peng HJ. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. *J Clin Med.* 2020;9(2):575. <https://doi.org/ggpixn9>.
41. World Health Organization (WHO). Coronavirus disease (COVID-19): Similarities and differences with influenza. Geneva: WHO; 2020 [cited 2020 Dec 2]. Available from: <https://bit.ly/3g9f9vK>.
42. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. *Pediatr Pulmonol.* 2020;55(5):1169-74. <https://doi.org/ggpixg2>.
43. Kragholm K, Andersen MP, Gerds TA, Butt JH, Østergaard L, Polcwiartek C, *et al.* Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide, register-based study. *Clin Infect Dis.* 2020:ciaa924. <https://doi.org/gg4f6m>.
44. Parri N, Lenge M, Buonsenso D. Children with Covid-19 in Pediatric Emergency Departments in Italy. *N Engl J Med.* 2020;383(2):187-90. <https://doi.org/ggtp6z>.
45. Brasil. Sociedade Brasileira de Pediatria. Novo coronavírus (COVID-19). Documento Científico No. 14; 2020 [cited 2020 Dec 2]. Available from: <https://bit.ly/3g9gra4>.
46. Kam KQ, Yung CF, Cui L, Tzer Pin Lin R, Mak TM, Maiwald M, *et al.* A Well Infant With Coronavirus Disease 2019 With High Viral Load. *Clin Infect Dis.* 2020;71(15):847-9. <https://doi.org/ggpixrp>.
47. Wise J. Covid-19: Study reveals six clusters of symptoms that could be used as a clinical prediction tool. *BMJ.* 2020;370. <https://doi.org/gg5q4r>.
48. Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q, *et al.* A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clin Infect Dis.* 2020;71(6):1547-51. <https://doi.org/ggpixkz>.
49. Heymann DL, Shindo N. COVID-19: what is next for public health? *Lancet.* 2020;395(10224):542-5. <https://doi.org/ggnntt>.
50. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. *J Med Virol.* 2020;92(6):612-7. <https://doi.org/ggpixcz>.
51. Páramo JA. Inflammatory Response in Relation to COVID-19 and Other Prothrombotic Phenotypes. *Reumatol Clin.* 2020. <https://doi.org/fk6c>.
52. Zhang C, Gu J, Chen Q, Deng N, Li J, Huang L, *et al.* Clinical Characteristics of 34 Children with Coronavirus Disease-2019 in the West of China: a Multiple-center Case Series. *PLoS Med.* 2020;17(6):e1003130. <https://doi.org/fk6d>.
53. Feng K, Yun YX, Wang XF, Yang GD, Zheng YJ, Lin CM, *et al.* [Analysis of CT features of 15 Children with 2019 novel coronavirus infection]. *Zhonghua Er Ke Za Zhi.* 2020;58(0):E007. <https://doi.org/ggqr9k>.